177
0 Kommentare
Medigene AG reports Financial Results and Business Update for Q1 2024 - Seite 3
In April 2024, the Company presented data for MDG1015 at the American Association for Cancer Research (AACR) Annual Meeting, which showed superior T cell functionality and tumor cell killing as well as a favorable safety profile of TCR-T cells armored and enhanced with Medigene’s PD1-41BB costimulatory switch protein. The poster data further illustrated that this costimulatory switch protein-mediated costimulatory signal is TCR-gated, indicating that costimulation only occurs when the TCR binds to the tumor antigen present on a tumor cell. As such, healthy cells that did not express the tumor antigen (NY-ESO-1) were not targeted, irrespective of their PD-L1 expression and no signs of toxicity were seen in diverse healthy tissues in vitro.
--- end of press release ---
About Medigene AG
Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing differentiated T cell therapies for treatment of solid tumors. Its End-to-End Platform is built on multiple proprietary and exclusive technologies that enable the Company to generate optimal T cell receptors against both cancer testis antigens and neoantigens, armor and enhance these T cell receptor engineered (TCR) -T cells to create best-in-class, differentiated TCR-T therapies, and optimize the drug product composition for safety, efficacy and durability. The End-to-End Platform provides product candidates for both its own therapeutics pipeline and partnering. Medigene’s lead TCR-T program MDG1015 is expected to receive IND/CTA approval in the second half of 2024. For more information, please visit https://medigene.com/
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Medigene AG
Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com
Lesen Sie auch
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.